All In Biotech

Drug Trial Radar · NCT05103332

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 663 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

663

Actual

Start

Nov 5, 2021

Primary completion

Dec 11, 2023

Study completion Sep 13, 2024

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.

Conditions

  • Hypertension

Interventions

  • IndapamideDrug

    Indapamide administered orally

  • AmlodipineDrug

    Amlodipine administered orally

  • OlmesartanDrug

    Olmesartan administered orally

  • PlaceboDrug

    Placebo administered by SC injection

  • ZilebesiranDrug

    Zilebesiran administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3
  2. Amlodipine: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3
  3. Olmesartan: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3

Locations

110 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Mesa, Arizona

  • Clinical Trial Site

    Tempe, Arizona

  • Clinical Trial Site

    Tempe, Arizona

  • Clinical Trial Site

    Bell Gardens, California

  • Clinical Trials Site

    Beverly Hills, California

  • Clinical Trial Site

    Canoga Park, California

  • Clinical Trial Site

    Carlsbad, California

  • Clinical Trial Site

    Encinitas, California

  • Clinical Trial Site

    Garden Grove, California

  • Clinical Trial Site

    Hollywood, California

  • Clinical Trial Site

    Huntington Beach, California

  • Clinical Trial Site

    Irvine, California

  • Clinical Trial Site

    Long Beach, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Mission Hills, California

  • Clinical Trial Site

    Oceanside, California

  • Clinical Trial Site

    Panorama City, California

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    Santa Clarita, California

  • Clinical Trial Site

    South Gate, California

  • Clinical Trial Site

    Tustin, California

  • Clinical Trial Site

    Upland, California

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Clearwater, Florida

  • Clinical Trial Site

    Coconut Creek, Florida

  • Clinical Trial Site

    Coral Gables, Florida

  • Clinical Trial Site

    Hollywood, Florida

  • Clinical Trial Site

    Hollywood, Florida

  • Clinical Trial Site

    Inverness, Florida

  • Clinical Trial Site

    Jacksonville, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Naples, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    Pembroke Pines, Florida

  • Clinical Trial Site

    Tampa, Florida

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.